Dr. Manel Esteller participates in the study published in Nature Communications, which identifies the molecular bases of this rare disease, in collaboration with the laboratory of Dr. Ethel Queralt (IBV-CSIC).

Two projects, directed by Dra. Maribel Parra and Dra. Montserrat Sanchez-Cespedes together with Dr. Octavio Romero, are admitted at the European Commission IP Booster program and the I-CERCA funded Gínjol Program, to advance in their process of valorization and explore its transfer capacity.

Dr. Ruth Risueño, Leukemia Stem Cells group leader at the Josep Carreras Leukemia Research Institute, is testing the effectiveness of a new group of compounds against acute myeloid leukemia thanks to the support of AGAUR and FEDER funds.

Dr. Montserrat Sánchez-Céspedes and Dr. Octavio Romero, from the Cancer Genetics group at the Josep Carreras Leukaemia Research Institute, have recently found that tumors with a genetically inactivated form of the chromatin remodeling protein SMARCA4 are highly sensitive to inhibitors of the KDM6 family of histone demethylases.

Manel Esteller, Director of Josep Carreras Leukaemia Research Institute, ICREA Researcher and Chairman of Genetics at the University of Barcelona, has been selected member of the Academia Europaea.

The course brought together hundreds of professionals, national and international, in the field of leukemias to delve into the challenges and opportunities that new genomic analysis techniques offer to improve the clinical diagnosis of malignant hemopathies.

Dr. Gerardo Ferrer, a researcher at the Josep Carreras Leukemia Research Institute and one of the four signatories of the project, will oversee the existence of epigenetic factors that could explain the development of this rare pediatric syndrome.

Most of the Spanish experts in acute lymphoblastic leukemia (ALL) met on May 26 and 27 at the 4th Workshop dedicated to this disease organized by the PETHEMA group, belonging to the Spanish Society of Hematology and Hemotherapy (SEHH).

Her project will focus on the physiological and molecular aspects of PIK3CA-related overgrowth spectrum (PROS) to study the impact that different PIK3CA mutation may have in the type, severity and progression of CLOVES and PIK3CA Related Conditions, and identify potential therapeutic targets.

The Josep Carreras Leukaemia Research Institute welcomes Expressions of Interest from excellent postdoctoral researchers to apply to the European Commission Marie Skłodowska-Curie Postdoctoral Fellowship call (MSCA-PF-2021).